The New Pharmaceutical World Order: Winners and Losers by 2030
Day 2 Global Pharma Outlook Stage
07/10/2026 16:15 - 17:00pm
Contributors
Claudia Palme : Senior Advisor and Independent Board Director - 55east LLC
Markus Sieger : Board Member Polpharma Group - Polpharma Group
Erika Porcelli : Chief Executive Officer - Pharmatech Associates, a USP company
Ronald T. Piervincenzi : CEO - United States Pharmacopeia (USP)
As the pharmaceutical industry shifts toward a more fragmented and multipolar landscape, competitive advantage is being redefined by geopolitics, regulation, and supply chain transformation. This panel will explore which regions, company types, and business models are best positioned to succeed by 2030 and which may struggle to adapt.
From strategic autonomy in Europe to industrial policy in the US and Asia, panellists will examine how global power dynamics are reshaping the future of pharma.
Discussion Points:
- What will define competitive advantage in pharma by 2030? Which regions are best positioned to lead and why?
- How are different company types (Big Pharma, generics, CDMOs, biotech) adapting their strategies?
- Will resilience outweigh cost efficiency as the dominant operating model?
- What strategic decisions today will determine tomorrow’s winners and losers?